Category Archives: Stem Cell Treatment


Healing by regeneration – Jamaica Observer

ONE year ago Sandrene Brown could not climb a flight of stairs without holding on to the rails for support. The simple act, which is routine for so many people, was just too painful.

However, she is now pain-free and can run up and down stairways to her liking.

In fact, like Brown, two other patients at St Ann's Bay Hospital might have similar stories to share after today. The two will be undergoing platelet-rich plasma procedures, one for shoulder impingement and the other for arthritis in both knees.

Orthopaedic surgeon at the hospital Dr Derrick McDowell told the Jamaica Observer that since he started doing stem cell surgeries early last year which, along with platelet-rich plasma procedures, forms part of the facility's thrust towards regenerative surgical procedures nearly 70 people have so far benefited.

I am, more or less, the only person to do them locally and in the Caribbean, Dr McDowell said of stem cell therapy.

[This] is where we do procedures to help people to regenerate to get back to the original quality and function.

On Friday I will be doing what's called platelet-rich plasma procedure, which is separating it from the blood, but with the stem cells we get it from the bone marrow. So we get the stem cells from the bone marrow and put it to the [affected] area under image guidance and, of course, we ensure that it does what it's supposed to do, he said.

The orthopaedic surgeon explained that since the bone transplant programme started at the hospital in 2013, adjunct to that was patients' healing, which led to regenerative surgical procedures.

Heal by regeneration, so stem cell surgery was the next logical step in that progress, he said. So what I started to do is what's called autologous somatic stem cells treatment so there are no ethical issues involved.

Autologous means the cells are obtained from the same individual, so the donor and recipient are the same.

So you basically go to the body reserves the body has stem cells and you isolate the stem cells and then you instil the stem cells under image guidance, such as ultrasound or X-rays, Dr McDowell said.

The doctor told the Observer that stem cell therapy has been working well for people who have muscular problems as well as ligament, joint and nerve issues.

But how exactly does the procedure help these people?

He explained that if a wound was to heal by regeneration, there would be no scar.

Cuts on your body with a scar were healed by scar formation So what you have there is skin, and that skin covers the area, but it doesn't have any sweat glands, no hair follicles; it doesn't look like normal skin, he explained.

[With regeneration] basically what we are doing is forcing the tissue to heal by regrowing its own native tissue, he said.

Dr McDowell said further that if a patient has arthritis, where the cartilage is damaged, we basically do a procedure to make the cartilage reform.

If you have nerves which have been damaged by trauma by chronic compression, like carpal tunnel syndrome and so on, we get the nerves to heal by growing back new nerves, he continued. And people who need joint replacement, for example, we can delay the operative surgery of doing joint replacement by giving them stem cells.

For Brown, though she told the Observer she was hesitant to do the procedure when she was told she had early stage arthritis, she feels much better having done it.

Honestly, I can climb stairs, run up stairs, run down stairs without any problem now, Brown said yesterday. I think it has done what it should've done; there is no relapse or anything like that.

Having branched off into regenerative procedures through stem cell surgery, Dr McDowell said what this does for the bone transplant programme at St Ann's Bay Hospital is improve healing rates.

So what's next?

Who knows? The sky is the limit, Dr McDowell responded.

The orthopaedic surgeon told the Observer that the stem cell therapy at the regional hospital is being done through a partnership with Surgix Jamaica Ltd, which is responsible for the preparation of the stem cells.

Surgix CEO Winfield Boban said yesterday that his company is trying to make treatment opportunities accessible to all Jamaicans.

Surgix provides the equipment and know-how in providing stem cell therapy across Jamaica and the Caribbean, but mostly Jamaica. Along with Dr McDowell, we provide equipment and the specialised staff and things like that, and all he does is now apply the stem cells, Boban said.

What we have done is to be able to make stem cell therapy as affordable and as accessible to the Jamaican community as possible, utilising innovators and pioneers such as Dr McDowell; we are getting the message across, Boban added.

The CEO pointed out that athletes such as Asafa Powell and Yohan Blake, if they wanted to do stem cell surgery, would have to travel to Germany, the United Kingdom, Switzerland, or the United States, but his company has brought the equipment to the shores of Jamaica.

We have been able to bring that science here and make it available not only for premier athletes to access it, but upcoming athletes too so we trying to level the playing field and make it accessible to the wider Jamaican community, he said.

Read more:
Healing by regeneration - Jamaica Observer

Global Parkinson’s Disease Drugs Market Outlook 2022 – Markets Insider

NEW YORK, Aug. 23, 2017 /PRNewswire/ -- Parkinson's disease belongs to the group of conditions called motor system disorders. This disease is a result of loss of dopamine producing neurons in the brain. The four primary symptoms of Parkinson's disease are tremors, rigidity, slowness of movement and postural instability. Although, there is no cure for Parkinson's disease, several medications are used to suppress the symptoms of the disease.

Read the full report: http://www.reportlinker.com/p05075843/Global-Parkinsons-Disease-Drugs-Market-Outlook.html

As per RNCOS report "Global Parkinson's Disease Drugs Market Outlook 2022", the global Parkinson's disease drugs market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global Parkinson's disease drugs market. The report provides insight about the major drivers, such as increasing awareness about Parkinson's disease and its treatment options, research grants and funds, for the global Parkinson's disease drugs market.

Furthermore, few challenges, such as patent expiry and high cost of treatment, which are hindering the growth of the global Parkinson's disease drugs market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global Parkinson's disease drugs market.

The global Parkinson's disease drugs market has been segmented on the basis of type of therapy into levodopa therapy, dopamine therapy, MAO-B inhibitor therapy, COMT inhibitor therapy, and other types of therapies. Among all the types, levodopa therapy is the first and most potent treatment for the Parkinson's disease. The benefits of the medication are witnessed soon after administration.

Apart from these types of therapies, various pharmaceutical and biotech companies are also developing stem cell therapy for the treatment of Parkinson's disease. Stem cell therapy is an evolving field which makes use of stem cells to treat or prevent a disease or condition, such as Parkinson's disease. Even a minimal success from this procedure can mean significant improvement in quality of life for patients.

Numerous companies, such as SanBio Inc and International Stem Cell Corp, are carrying out clinical trials for stem cell therapies for the treatment of Parkinson's disease. Hence, stem cell therapy presents great opportunities for the growth of global Parkinson's disease drugs market in the coming years.

Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global Parkinson's disease drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global Parkinson's disease drugs industry. The drugs pipeline of Parkinson's disease has also been mentioned in the report.

Read the full report: http://www.reportlinker.com/p05075843/Global-Parkinsons-Disease-Drugs-Market-Outlook.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com __________________________ Contact Clare: rel="nofollow">clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/global-parkinsons-disease-drugs-market-outlook-2022-300508683.html

SOURCE Reportlinker

Read more here:
Global Parkinson's Disease Drugs Market Outlook 2022 - Markets Insider

Stem Cell Therapy for Infections by Resilient Bacteria – Financial Tribune

According to data released by the Food and Waterborne Diseases Office of the Health Ministry, an average of 15% of hospital patients suffer from nosocomial infections. A nosocomial infection is an infection acquired in hospital by a patient who was admitted for a reason other than the infection. The severity of hospital-acquired infections depends on the location and type of infection, said Abbasali Imani Fouladi, the scientific secretary of the 18th International Congress of Microbiology, which will be held on Aug. 29-31 at Tehran University of Medical Sciences, ISNA reported. The use of stem cells and their significant role in treatment of the infectionsin particular, antibiotic-resistant infectionsis a key topic that will be discussed by domestic and foreign specialists at the conference. Sometimes ulcers which are resistant to conventional treatment, respond positively and swiftly to stem cell treatments, he explained, adding that officials from Council for Stem Cell Sciences and Technologies (affiliated to Vice-Presidency for Science and Technology) have been invited to the event that will be attended by scientists from Spain, Italy, UK, and France. Four workshops will be held on the sidelines of the meeting. Stating that with resistance to antibiotics becoming more common, there is greater need for alternative treatments, he said, Currently there are 12 strains of bacteria in need of new antibiotics or alternative treatments. The event is co-sponsored by the Health Ministry, TUMS, Pasteur Institute of Iran, Razi Vaccine and Serum Research Institute, and Ilam University of Medical Sciences, according to the congress website (ismcongress.ir). Nosocomial infections occur worldwide and affect both developed and resource-poor countries. Healthcare-associated infections are among the major causes of death and increased morbidity among hospitalized patients. They are a significant burden both for the patient and public health. According to the World Health Organization, HAIs add to functional disability and emotional stress of the patient and may in some cases, lead to disabling conditions that reduce the quality of life. Nosocomial infections are also one of the leading causes of death. The economic costs are considerable. The increased length of hospital stay for infected patients is the greatest contributor to cost. While the prevalence rate of HAIs is 30% in lower-income countries, the average rate is around 6-11% in developed countries, according to Dr. Hossein Masumi-Asl, head of the Food and Waterborne Diseases Office. The most frequent nosocomial infections are infections of surgical wounds, urinary tract infections and lower respiratory tract infections, he said. According to the official, the highest prevalence of nosocomial infections occurs in intensive care units and in acute surgical and orthopedic wards. Infection rates are higher among patients with increased susceptibility because of old age, underlying disease, or chemotherapy.

Originally posted here:
Stem Cell Therapy for Infections by Resilient Bacteria - Financial Tribune

Vitamin C injections could play a role in treating blood cancers – NHS Choices

Monday August 21 2017

AML is an aggressive cancer of the white blood cells

"Super-strength vitamin C doses could be a way to fight leukaemia," the Mail Online reports. Research in mice found vitamin C could help combat the effect of a mutated gene that can cause uncontrollable stem cell growth and trigger the onset ofacute myeloid leukaemia (AML).

AML is an aggressive cancer of the white blood cells that usually affects older people. It is thought that some cases of AML are caused by a mutation in the Tet Methylcytosine Dixoygenase 2 (TET2) gene. This gene helps mature stem cells into specialised white blood cells. The mutation can lead to uncontrollable growth of cancerous cells leading to AML.

The researchers used mice to explore whether use of vitamin C could restore the TET2 gene to working order and help slow the progression of leukaemia.

The study found that using high doses of vitamin C intravenously did in fact suppress the growth of leukaemia cancer stem cells in the mice.

Although this does pave the way for future therapeutic approaches, this study was very early stage research in mice, and therefore would require further investigation and trials in humans before any treatment based on the findings could beoffered to patients.

Also, the dose used was far higher relative to weight, than would be safe in humans. It would be the equivalent of a human taking 300g of vitamin C,which would mean eating more than 5,000 oranges. So scientists would also have to find a way to lower the dose while achieving the same beneficial effect.

The study was carried out by researchers from several institutions, including New York University and Monash University in Australia. It was funded by numerous institutions such as the US NIH, the Leukaemia & Lymphoma Society and the Chemotherapy Foundation.

The study was published in thepeer-reviewed scientific journal Cell.

The UK media's coverage on this topic was generally accurate, highlighting that this is not a treatment that would be used by itself, but instead in combination with other approaches, such as chemotherapy.

This was an animal study which investigated whether treatment with vitamin C could restore function of Tet Methylcytosine Dixoygenase 2 (TET2) and therefore block the progression of leukaemia in mice.

TET2 is one of the most frequent mutations in diseases and cancers of the blood such as leukaemia. The TET2 gene encodes a protein involved in the production of bone marrow and blood cells. As a result, defects and mutations of TET2 can negatively affect the process which causes stem cells to turn into blood cells. In turn, this can promote the progression of leukaemia.

The researchers wanted to explore the role of TET2 deficiency in the maintenance of leukaemia stem cells.

The researchers further investigated whether vitamin C could be useful in the treatment of blood cancers. This is because treatment with vitamin C has previously been tested in solid tumours (tumours located in one part of the body, such as the lungs) and in some cases, been found to result in better patient outcomes.

Animal studies such as this are useful for early stage research. Butwhile there are many genetic similarities between mice and humans, we aren't identical. Therefore further testing is required in people to be sure of the effect of any treatment.

The researchers implanted leukaemia stem cells, extracted from humans, into mice and also used mice that were deficient in TET2.

To determine the effects of mutations that could reduce TET2 function, the mice were genetically engineered so that the TET2 gene could be switched on or off.

High doses of vitamin C were then administered intravenously to the mice and the function of TET2 and cell behaviour was studied.

The researchers also tested the use of vitamin C alongside PARP inhibitors. PARP inhibitors are a class of chemotherapy drugs that can help repair damaged DNA.

The researchers found that when the function of TET2 was switched off in the mice, abnormal stem cell behaviour occurred. This was reversed however once the function of TET2 was switched back on, confirming that loss of function of TET2 would in fact play a role in the formation of cancerous stem cells in diseases such as leukaemia.

In the TET2 deficient mice, the effects of TET2 deficiency were reversed following having intravenous vitamin C administered. The vitamin C treatment also induced the stem cells to mature and suppressed the growth of leukaemia cancer stem cells in the mice implanted with cell lines from human patients with leukaemia.

The researchers also found that following vitamin C treatment, the leukaemia cell lines were more sensitive to treatment with PARP inhibitors.

The researchers concluded: "We have found that targeted restoration of Tet2 is sufficient to block aberrant self-renewal of pre-leukemic stem cells. Similarly, vitamin C, by enhancing the activity of TET family dioxygenases, acts as a pharmacologic mimic of Tet2 restoration. Moreover, genetic or pharmacological restoration of TET activity confers an emergent vulnerability in leukemia cells, rendering them more sensitive to PARP inhibitors. Together, these results suggest new therapeutic strategies for clonal hematopoiesis, MDS and AML."

This mouse study explored whether treatment with vitamin C could restore function of TET2 and therefore block the progression of blood cancers like leukaemia.

It found that using high doses of vitamin C intravenously did in fact suppress the growth of leukaemia cancer stem cells in the mice implanted with cell lines from human patients with leukaemia.

It also reported that using vitamin C alongside existing treatment with PARP inhibitors helped reduce the progressions of the disease.

The researchers suggest that in the future, vitamin C could be used alongside chemotherapy and other conventional treatment forms.

This is exciting early stage research, with potential to pave the way for future treatment options for leukaemia and other blood cancers.

One of the challenges of treating acute myeloid leukaemia is that patients are usually older so it is often not safe to use very aggressive forms of chemotherapy. Hopefully vitamin C, or a similar substance, could help enhance the effects of milder forms of chemotherapy.

However, because this was an animal study, these results would need further investigation and have to undergo clinical trials in humans before new treatments based on these findings could be offered to patients.

It is far too soon to start taking high doses of vitamin C on the basis of this research, especially as large amounts of the vitamin (more than 1g per day per person) can cause stomach upsets. Some mice in this study received 100 milligrams, which would be equivalent to humans receiving 300g of pure vitamin C.

From what we know about AML, it would seem that the one way to reduce your chances of developing this cancer is to quit smoking.

See original here:
Vitamin C injections could play a role in treating blood cancers - NHS Choices

STONE: Certain medical practices can prey on false hopes – Odessa American

Its human nature to want a quick fix in resolving issues or problems. Getting maximum results with minimal effort certainly has its appeal. From Thigh Masters and Bowflexes to The Clapper and Ginsu knives, the promise for rapid results and convenience can draw consumers in like the late-night glow of the TV infomercials selling these items.

But, lets be honest, these examples may have yield their desired results, but most products end up being a total disappointment and waste of money. This is also the case with certain medical procedures or therapies claiming to fix certain ailments or chronic conditions. As a patient-consumer, its important to do your research and not let emotions or false hopes guide you into making a potentially expensive or even risky decision involving your health.

One item in general, stem cell therapy, has been getting quite a bit of attention of late. Many may ask, what are stem cells? Stem cells are cells that have the potential to develop into many different types of cells. Think of them as a blank canvas which can divide and become specialized cells within the body such as blood, liver, or muscle cells. Stem cell therapy acts by introducing these cells into some areas of the body, to which the stem cells can divide regularly to regenerate and/or repair existing tissue. Stem cell therapy has long been used by physicians to treat certain types of cancers, such as leukemia and lymphoma as well as treating some bone, skin, and corneal eye injuries. But, while stem cells continue to be studied as potential treatments for other ailments and conditions, there are very few of these treatments currently that have been proven to be effectivelet alone safe.

With catchy, even gimmicky, tag lines like make me walk again, feel young again, or no surgery, no side effects, clinics (both in the United States and outside of it) are offering stem cell therapy to treat a laundry list of conditions. The problem with it is patient testimonials and gimmicky marketing techniques can be misleading. One resource beneficial in better understanding stem cell therapies is the International Society for Stem Cell Research (ISSCR). It represents academia and industry on a broad range of issues that affect the well-being of patients and their families, and strives to educate the public and government regulators on the basic principles of stem cell science and the realistic potential for new medical treatments and cures.

According to the ISSCR, when there is no existing or effective treatment for a disease or condition it is easy to understand why you may feel there is nothing to lose from trying something new, even if it isnt proven. Unfortunately, most of the unproven stem cell treatments for sale throughout the world carry very little promise of actual benefit and very real risks.

Many stem cell therapy clinics may offer the use of a patients own cells, also known an autologous transplant. In theory, your immune system would not attack your own cells if they were used in a transplant. However, the processes by which the cells were acquired, grown and then reintroduced into the body would carry risks. Here are just a few known risks of autologous stem cell treatments:

If you have thought about or are considering stem cell therapy, first get the guidance of your primary healthcare provider. They can help guide you in obtaining the right literature and evidence in help making the right decision for the safest and most effective treatments available. Snake oil salesmen exist in every industryincluding those wearing white lab coats. Choose your care wisely.

Continued here:
STONE: Certain medical practices can prey on false hopes - Odessa American

Forever Labs preserves young stem cells to prevent your older self from aging – TechCrunch

Forever Labs, a startup in Y Combinators latest batch, is preserving adult stem cells with the aim to help you live longer and healthier.

Stem cells have the potential to become any type of cell needed in the body. Its very helpful to have younger stem cells from your own body on hand should you ever need some type of medical intervention, like a bone marrow transplant as the risk of rejection is greatly reduced when the cells are yours.

Mark Katakowski spent the last 15 years studying stem cells. What he found is that not only do we have less of them the older we get, but they also lose their function as we age.So, he and his co-founders Edward Cibor and Steve Clausnitzer started looking at how to bank them while they were young.

Clausnitzer banked his cells two years ago at the age of 38. So, while he is biologically now age 40, his cells remain the age in which they were harvested or as he calls it, stem cell time travel.

Steven Clausnitzer with his 38-year-old banked stem cells.

There are places offering stem cell therapy and Botox, he said.

Forever Labs is backed by a team of Ivy League-trained scientists with decades of experience between them. Jason Camm, chief medical officer for Thiel Capital, is also one of the companys medical advisors however, the startup is quick to point out it is not associated with Thiel Capital.

The process involves using a patented device to collect the cells. Forever Labs can then grow and bank your cells for $2,500, plus another $250 for storage per year (or a flat fee of $7,000 for life).

The startup is FDA-approved to bank these cells and is offering the service in seven states. What it does not have FDA approval for is the modification of those cells for rejuvenation therapy.

Katakowski refers to what the company is doing as longevity as a service, with the goal being to eventually take your banked cells and modify them to reverse the biological clock.

But that may take a few years. There are hundreds of clinical trials looking at stem cell uses right now. Forever Labs has also proposed its own clinical trial to take your stem cells and give them to your older cells.

Youll essentially young-blood effect yourself, Katakowski joked of course, in this case, youd be using your own blood made from your own stem cells, not the blood of random teens.

See more here:
Forever Labs preserves young stem cells to prevent your older self from aging - TechCrunch

Medical Tourism Corporation Announces Stem Cell Therapy in Mexico With GIOSTAR – NBC Right Now

The two entities join hands for all-inclusive stem cell treatment in Los Algodones, Tijuana, and Guadalajara. Package includes personalized therapy protocol, travel assistance, and more. GIOSTAR is a global stem cell leader with more than 4,000 people treated.

DALLAS - August 14, 2017 - (Newswire.com)

The major medical tourism facilitator has added another much-needed treatment to its comprehensive list of medical services, stem cell treatment in Mexico, as a way of helping people with degenerative, immunological, and blood-based diseases receive alternative healthcare and lead a happy, healthy life.

About GIOSTAR Mexico

Founded by a leading stem cell scientist, Dr. Anand Srivastava who is credited with setting up stem cell research programs in Sal Research Institute, UCSD, UCI and Sanford Burnham Institute, GIOSTAR is a visionary organization in the field. With its headquarters in San Diego and multiple top-notch facilities, offices and hospitals in various locations including India, Mexico, Brazil and Colombia, the venture is expanding its reach and making treatment for several devastating immunological and blood- related diseases accessible for all.

GIOSTAR Mexico offers stem cell therapy in Tijuana, Guadalajara, and Los Algodones. Current treatments include Diabetes Type I and Type II, Lupus, Multiple Sclerosis, Crohn's disease, and Spinal Cord Injuries (SCI), among others. The therapies for Alzheimer's, Autism, Anti-Aging Treatments, Parkinson's disease, Heart and Retinal Degeneration, and many more diseases are being developed by the dedicated and skilled members of the institute.

Some prominent features of GIOSTAR are:

About Medical Tourism Corporation (MTC)

The Texas-based Medical Tourism Corporation is a Better Business Bureau (BBB) accredited health tourism organizer. The corporation aims to connect medical tourists from all over the world to excellent healthcare services without the underlying stress. The most daunting part of the medical tourism process is the lack of information about quality treatments in Mexico, India, and other health tourism hubs. MTC emerges as a helping hand, and assists its customers in planning every little detail of their medical trip and even offers generous post-op services and follow-up care for a safe recovery.

With the introduction of alternative therapies for taxing and draining conditions, such as stem cells for Parkinson's in Mexico, the organization is expanding its arsenal of services and treatments offered.

Medical Tourism Corporation has recently partnered with GIOSTAR with the goal of making quality healthcare come true. The two entities have collaborated to offer personalized protocols for various conditions and injuries, including stem cell therapy for spinal injuries in Mexico.

Aiming to provide exemplary stem cell treatment in Mexico, MTC provides a host of services and features that set the venture apart:

What to Expect?

The National Institutes of Health (NIH) estimates up to 23.5 million Americans suffer from autoimmune diseases. All that is standing between these patients and life-altering medical treatments is a border away.

This timely collaboration between GIOSTAR and MTC is an important step forward in bridging the gap between demand and supply of effective alternative treatments for people suffering from the aforementioned ailments when conventional therapies fail to treat. More information on stem cell therapy in Mexico is available on the official website of Medical Tourism Corporation.

Related Links Stem Cell Treatment for Diabetes Type 1 and 2 in Mexico Stem Cell Treatment for Arthritis in Mexico

Related Images

Press Release Service by Newswire.com

Original Source: Medical Tourism Corporation Announces Stem Cell Therapy in Mexico With GIOSTAR

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and have questions or removal reuqests please contact pressreleases@franklyinc.com

Originally posted here:
Medical Tourism Corporation Announces Stem Cell Therapy in Mexico With GIOSTAR - NBC Right Now

Local chiropractor educating patients about stem cell treatments – WZZM

Denise Pritchard, WZZM 12:44 PM. EDT August 14, 2017

Woman's Bones

GRAND RAPIDS, MICH. - Stem cell injections are being used to treat all sorts of illness, from joint pain to tissue damage. Dr. Michael Kwast is a chiropractor who's sold on the benefits of stem cell treatments.

He joined The Exchange to explain how they work and describe the results hes seen for patients.

Dr. Kwasts group, Medical Services Providers, is affiliated with the Stem Cell Institute of America.

For more information about stem cell therapy, visit http://www.stemcellgrandrapids.com. Or, you may attend a free seminar on Aug. 21 at 7 p.m. Its at 475 Lake Michigan Dr. NW in Grand Rapids. Register now by calling 616-888-3160.

Make it easy to keep up to date with more stories like this. Download the WZZM 13 app now.

Have a news tip? Email news@wzzm13.com, visit our Facebook page or Twitter.

2017 WZZM-TV

Read more from the original source:
Local chiropractor educating patients about stem cell treatments - WZZM

India’s Advancells Reports Successful Reversal of MS in Single Patient Using Stem Cell Therapy – Multiple Sclerosis News Today

Advancellssays its stem cell-based therapy completely reversed multiple sclerosis (MS) in an Indian pilot trial with only one MS patient.

The patient, Rahul Gupta, was diagnosed with MS seven years ago and has since suffered multiple relapses. His disease was progressing fast and he was quickly losing his ability to walk. Gupta, who lives in New Zealand, approached Advancells a company based in the Indian state of Uttar Pradesh that specializes in the use of stem cells for therapeutic purposes.

After my last relapse, I became determined to look for alternative treatments for multiple sclerosis,Gupta said in a press release. I started looking on the net and found that stem-cell therapy [offers] hope for people suffering with MS [and] that it is safe and would not harm me in any way. I was determined to undergo stem-cell treatment, as my illness was progressing very quickly.

Gupta enrolled inAdvancells adult stem-cell therapy program as the trials single patient. In the procedure carried outin June at a New Delhi clinic doctors isolated stem cells from his bone marrow and re-infused them back into the patientat specific points. Apart from this procedure, Gupta underwent only physiotherapy and a dietary routine.

Straight after the treatment I saw major improvements, he said. I could walk a lot better, could climb stairs which I was unable to do after 2012 and even go on the treadmill.

Dr. Lipi Singh, head of technology at Advancells, said the company is frequently approached by MS patients from around the world who want to participate in its program.

Patient selection is a key criterion for us and Rahul suited the criteria perfectly, Singh said. He is young and still at a moderate level of the disease and in a very positive frame of mind. Patients at this stage are best suited for this kind of treatment and thus we decided to accept him as a pilot case.

Singh now expects to review Guptas response sometime this fall.

It will take approximately three months for us to review changes in the magnetic resonance imaging of the patient, but the drastic changes in symptoms clearly are an indication of the fact that the treatment is working and could become a hope for millions of patients across the world who are suffering from this disease. Singh said.

He added: This is a good start to a lengthy research phase, but it seems that we are on the right track and hopefully we will be able to make a significant contribution in eradicating not only MS but a host of untreatable diseases existing today.

See more here:
India's Advancells Reports Successful Reversal of MS in Single Patient Using Stem Cell Therapy - Multiple Sclerosis News Today

Clinical trials of stem cell-based "functional cure" for type 1 diabetes underway – New Atlas

A new treatment currently undergoing human clinical trials could see the end of pin prick tests for diabetics (Credit: bacho123456/Depositphotos)

A human clinical trial examining the safety and efficacy of a "functional cure" for type 1 diabetes is currently underway. Trials of the novel islet cell replacement therapy developed by ViaCyte involve a device containing stem cells being implanted into a patient with type 1 diabetes. It's hoped these cells will then mature into human islet tissue with insulin-producing beta cells that produce insulin on demand.

So far, 2017 is proving to be an exciting year for breakthroughs in diabetes research, particularly in regards to treatments for type 1 diabetes. We have seen two very promising developments based in gene therapy, while a human trial for a type 1 diabetes vaccine is currently underway in Finland targeting a viral group known to trigger the disease.

UPGRADE TO NEW ATLAS PLUS

More than 1,500 New Atlas Plus subscribers directly support our journalism, and get access to our premium ad-free site and email newsletter. Join them for just US$19 a year.

The new treatment developed by ViaCyte is being described as a "functional cure" in that it could replace the missing insulin cells in a diabetic patient, as opposed to a more direct "cure" which would address the autoimmune roots of the disease.

The treatment being trialed piggybacks off prior working knowledge of islet cell transplantation being successful in patients with type 1 diabetes. For some time, patients with the disease have been treated with pancreatic cells from organ donors, successfully liberating them from insulin injections.

"Islet transplants have been used to successfully treat patients with unstable, high-risk type 1 diabetes, but the procedure has limitations, including a very limited supply of donor organs and challenges in obtaining reliable and consistent islet preparations," says trial investigator James Shapiro. "An effective stem cell-derived islet replacement therapy would solve these issues and has the potential to help a greater number of people."

The new treatment involves a device called PEC-Direct, which holds stem cell-derived pancreatic progenitor cells and is implanted into a patient. This allows those cells to mature in the body, becoming islet tissue that includes the beta cells that produce insulin when needed.

Because these stem cells can be replicated in a laboratory, this process doesn't rely on a finite amount of organ donor cells and allows the treatment to be delivered to a large number of patients quickly and easily. Unlike current similar treatments, which require invasive transplantation directly into the liver, this new device can be easily implanted superficially under the skin.

The first patients being implanted with small-format versions of the devices will evaluate the safety of the treatment. A second, larger cohort will be recruited later in 2017 to also evaluate its safety and also ascertain the treatment's efficacy. If implantation and cell maturation is demonstrated, the trials will measure how much clinically relevant insulin is being delivered by the treatment.

This new strategy being trailed by ViaCyte is hoped to have demonstrable and definite efficacy within the next two years, meaning the practical deployment may not be too far away if all goes well.

As well as the PEC-Direct for treating type 1 diabetes, the company is also developing a broader device called PEC-Encap, which could be used to treat all patients with diabetes who use insulin, type 1 and type 2. If these trials are successful they could prove to be a watershed moment in the treatment of diabetes.

Source: ViaCyte

Read more from the original source:
Clinical trials of stem cell-based "functional cure" for type 1 diabetes underway - New Atlas